Clinical Trials in Philadelphia

Showing 221-240 of 9,968 trials

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

IDEAYA Biosciences160 participantsStarted Jul 2023

Scottsdale, Arizona, United States • La Jolla, California, United States • Palo Alto, California, United States +15 more locations

RECRUITINGPHASE2< 1 mile

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Carcinoma, Non-Small-Cell Lung

Johnson & Johnson Enterprise Innovation Inc.130 participantsStarted Dec 2024

Farmington, Connecticut, United States • New Haven, Connecticut, United States • Miami, Florida, United States +33 more locations

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Find Trials by Condition in Philadelphia

Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

An International Observational Study of Adults With Acute Infection

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Premedication to Reduce Amivantamab Associated Infusion Related Reactions